Navigation Links
Dong-A PharmTech Co., Ltd. and Dr. Falk Pharma GmbH Announce Positive Data in Portal Hypertension With Udenafil
Date:6/13/2011

SEOUL, South Korea, June 13, 2011 /PRNewswire/ -- Dong-A PharmTech Co., Ltd. and Dr. Falk Pharma GmbH announced positive results from an initial safety and efficacy portal hypertension study in man using udenafil, its new long-active phosphodiesterase inhibitor. The data was presented by the principal investigator, Prof. Wolfgang Kreisel, Department of Gastroenterology, Hepatology, Endocrinology and Infectious Diseases, University of Freiburg, Freiburg, Germany.

In a 1-week open-label, multicenter phase 2 trial, 20 patients with portal hypertension (Child-Pugh A/B) that met the selection criteria were given a daily oral dose of one of four dose levels of udenafil. The primary efficacy endpoint was the change of hepatic venous pressure gradient (HVPG) from day 0 (pre dose) to day 6 post dose.  A total of 7 of 20 patients showed a response defined as a HVPG reduction of < 12 mmHG or by > 20% after one week of daily dosing.  In the high dose group, HVPG was lowered in 4 of the 5 patients by more than 10% after administration of study drug on day 0 or day 6.  No decrease of mean arterial blood pressure was seen in any of the four dose groups.  Standard liver biochemical tests did not change during the study and no adverse events were attributed to the study drug.

The results of this study show that the oral application of the new PDE-5 inhibitor udenafil lowers HVPG in an acute setting without any systemic cardiovascular side effects.  Effectiveness appears to be dose related.  Further study is contemplated using a placebo controlled design and a longer study duration.

About Dong-A PharmTech Co., Ltd.

Dong-A PharmTech is a late-stage pharmaceutical company incorporated in Korea, focused on the development and commercialization of udenafil worldwide excluding Korea.

About Dr. Falk Pharma GmbH .

Dr. Falk Pharma GmbH is one of the most recognized companies worldwide in gastroenterology.  Dr. Falk Pharma products are sold in more than 60 countries.  The Falk Foundation, which is associated with the Company, provides medical information via international symposia, forums and postgraduate courses.  Over the past 50 years the Falk Foundation has sponsored more than 200 symposia in which over 100,000 physicians from 110 countries have come together to advance knowledge in gastroenterology and hepatology.

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to FDA review and approval, product development and acceptance, manufacturing, competition, and/or other factors, which are outside the control of the Company.

Contact:
            Mr. Won Geun KIM
            General Manager
            Tel: +82 2 560 8008
            Fax: + 82 2 563 6517
            Email: wgkim@donga.co.kr


'/>"/>
SOURCE Dong-A PharmTech Co., Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil
2. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
3. Dong-A PharmTech Co., Ltd. Announces Start of Phase III Trials for Udenafil, Its New Erectile Dysfunction Drug Under Development
4. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
(Date:6/23/2016)... N.J. , June 23, 2016  Guerbet announced ... Premier Inc.,s Supplier Horizon Award . ... year, Guerbet was recognized for its support of Premier ... creation through clinical excellence, and commitment to lower costs. ... to receive this recognition of our outstanding customer service ...
Breaking Medicine Technology:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, ... Elite. The attorneys chosen by their peers for this recognition are considered among the ... Traurig Shareholders received special honors as members of this year’s Legal Elite Hall of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone ... executive with extensive sequencing and genomics experience, as Vice President of North American Capital ... will be responsible for leading the sales team in the commercialization of the HTG ...
Breaking Medicine News(10 mins):